EPILOG PARTNERS, LP.
EPILOG PARTNERS, LP. is a Series C+ and buyout fund in the US writing $50M–$200M checks into healthcare-tech, pharma-services, payer-services and provider-services.
- Stages
- Series C+, buyout
- Sectors
- healthcare-tech, pharma-services, payer-services, provider-services
- Check size
- $50M–$200M
- Invests in
- US-wide
- Actively investing
- Yes
- Founded
- 2020
- Assets under management
- $181.6M
Thesis
Epilog Partners, LP is a private equity firm founded in 2020, specializing in the healthcare sector. Their investment thesis centers on tech-enabled payer, provider, and pharma services companies that demonstrably improve clinical, financial, and experiential outcomes. The firm primarily engages in leveraged buyouts of profitable, high-growth companies, targeting equity investments between $50 million and $200 million. Their strategy is research-centric and thesis-driven, guiding investment decisions and value maximization. With headquarters in Boston, MA, and an office in Dallas, TX, Epilog Partners focuses its investments within the United States, preferring later-stage opportunities suitable for buyouts. One filing from April 2026 reported approximately $181.6 million in discretionary regulatory assets under management (AUM).
Common questions
Does EPILOG PARTNERS, LP. invest at the Series C+ stage?
Yes. EPILOG PARTNERS, LP. lists Series C+ and buyout among the stages it invests in.
What check size does EPILOG PARTNERS, LP. write?
EPILOG PARTNERS, LP. writes $50M–$200M checks.
Where does EPILOG PARTNERS, LP. invest?
EPILOG PARTNERS, LP. invests in the US.